The First Hospital Affiliated to AMU (Southwest Hospital)
Welcome,         Profile    Billing    Logout  
 8 Trials 
21 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chen, Lei
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Checkmark Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Checkmark Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Checkmark From LUCENT 1 trial for ulcerative colitis
More
Completed
3
1281
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis
01/21
05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Active, not recruiting
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
TQB2450-III-08, NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Recruiting
3
392
RoW
TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Biliary Cancer
03/22
02/23
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Recruiting
3
480
RoW
Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatocellular Carcinoma
08/24
12/26
NCT06492460: 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma

Recruiting
3
422
RoW
Drug:Cisplatin, CDDP Drug
Sun Yat-sen University, Hunan Cancer Hospital, Guilin Medical University, China, Jiangsu Cancer Institute & Hospital, Xiangya Hospital of Central South University
Squamous Cell Carcinoma of Head and Neck
09/29
07/33
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

Not yet recruiting
3
408
RoW
TQF3510 (Semaglutide Injection), Wegovy®
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Obesity
07/26
08/26
TSL-CM-JSSPMFSL-Ⅲ, NCT06068465: A Study of the Safety and Efficacy of Pimavanserin in Patients with Parkinson's Disease Psychosis

Recruiting
3
248
RoW
pimavanserin tartrate, placebo
Tasly Pharmaceutical Group Co., Ltd
Parkinson's Disease Psychosis
06/25
01/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT03977480: Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis

Terminated
2
70
RoW
Hemay007, Placebo
Tianjin Hemay Pharmaceutical Co., Ltd
Ulcerative Colitis
08/22
08/22
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

Not yet recruiting
2
318
RoW
HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes
04/25
04/25
NCT06493747: Acupuncture + Neuromodulation for Post-Stroke Aphasia

Recruiting
N/A
82
RoW
Combined Low- and High-Frequency rTMS Intervention, Combined High- and Low-Frequency rTMS Intervention, rTMS, rTMS + Acupuncture, Control Group, Acupuncture
Shanghai Yueyang Integrated Medicine Hospital
Aphasia, Rehabilitation
10/24
01/25
NCT06762613: AI Guided System for Lung Puncture Procedure.

Not yet recruiting
N/A
220
RoW
Generative AI Based Puncture Surgery Navigation System, Cone beam CT
Wuhan Union Hospital, China
Lung Nodules
05/25
05/25
Liang, Houjie
NCT04329429: A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer

Active, not recruiting
2
57
RoW
RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection
RemeGen Co., Ltd.
Biliary Tract Cancer
11/23
06/24
Xiang, Xiaomei
PRECAR, NCT03588442: Prospective Surveillance for Very Early Hepatocellular Carcinoma

Recruiting
N/A
10000
RoW
Eastern Hepatobiliary Surgery Hospital
Carcinoma, Hepatocellular
07/22
07/23
Song, Zhiqiang
NCT06561711: Optimization of Minocycline for Helicobacter Pylori Rescue Treatment

Recruiting
4
476
RoW
Vonoprazan, Bismuth Potassium Citrate, Tetracycline,Metronidazole, Minocycline,Metronidazole
Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection
08/26
08/26
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Completed
3
336
Canada, RoW
Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2
Reistone Biopharma Company Limited
Atopic Dermatitis
08/22
05/23
NCT06552520: To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Not yet recruiting
3
500
RoW
TQH2722 injection, Placebo of TQH2722 injection
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Atopic Dermatitis
10/25
06/26
MARBLE-23, NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Active, not recruiting
2/3
645
RoW
SHR0302 Ointment, SHR0302 Ointment 2%, SHR0302 Ointment 1%, SHR0302 Ointment 0.5%, Vehicle, Placebo
Reistone Biopharma Company Limited
Atopic Dermatitis
09/23
07/24
NCT06228560: Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Recruiting
2
200
RoW
LP-003, Placebo, Omalizumab
Longbio Pharma
Chronic Spontaneous Urticaria
01/25
01/25
Wu, Hongbo
ERR-NSCLC-01, NCT06618391: Local Injection and Systemic Therapy in the Treatment of NSCLC.

Not yet recruiting
2
84
NA
Envafolimab, PD-L1, Recombinant human endostatin, Endostar, recombinant human adenovirus type 5, OncorineR
Henan Cancer Hospital
Non-small Cell Lung Cancer
03/26
10/26
NCT04989153: Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer

Recruiting
N/A
5000
RoW
pepsinogen
Second Affiliated Hospital, School of Medicine, Zhejiang University, Jilin City People's Hospital, No. 924 Hospital of the People's Liberation Army of China, Kunshan Hospital of Traditional Chinese Medicine, Chinese PLA General Hospital, Sichuan Provincial People's Hospital, Affiliated Hospital of Southwest Medical University, Zhongshan Hospital Xiamen University, Jingzhou Hospital of Traditional Chinese Medicine, Changhai Hospital
Gastric Cancer, Precancerous Lesion, Helicobacter Pylori Infection
12/22
12/23

Download Options